Stephanie Link, managing director at TIAA, scooped up shares of two beaten-down names for her model portfolio on Wednesday.
The FMHR traders look at retail earnings, and the health of biotech stocks right now.
As the first quarter comes to a close, one sector notably stands out in the negative column: biotech.
Amid a tough year for markets, "Fast Money" traders looked to what they deemed best-in-class stocks that could outperform ahead.
The Fast Money trades present their personal Oscar's to Oscar worthy stocks including Alexion pharmaceuticals, PayPal, and more.
The "Fast Money" traders give you 4 trades in honor of the Oscars coming up this weekend.
Jim Cramer doesn't love fossil fuels, but he is willing to bet that this energy stock goes higher.
U.S. stock index futures pointed to a mostly higher open on Wednesday after a better-than-expected ADP jobs report.
Using Kensho, a quant tool used by hedge funds, CNBC Pro searched for the best stocks to buy during fourth-quarter earnings season.
Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.
U.S. stocks closed mostly lower Tuesday but off session lows as oil prices stabilized and biotech stocks gained.
Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.
U.S. stock index futures indicated a lower open as investors weighed the possibility of a December rate hike, amid the release of GDP and earnings.
The Fed turned up the heat around a possible December rate hike, just as the government is about to release a report expected to show sluggish GDP growth.
Jim Cramer says to wait for this group to come in before pouncing on this stock when he gave his take on caller favorite stocks.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
As the third-quarter earnings season gets underway, here are some lesser-known plays from some of today's top money managers.
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
Fears of tepid global world took center stage this week once again, sending equity benchmarks across the board in the red this week.
CNBC Pro reached out to top Wall Street fund managers to find out where they are putting money to work ahead of a potential Fed rate increase.